Division of Neurology, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand; Bumrungrad International Hospital, Bangkok 10110, Thailand.
Social and Administrative Pharmacy Excellence Research (SAPER) Unit, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, 447 Sri-Ayudthaya Road, Phayathai, Ratchathewi, Bangkok 10400 Thailand.
Mult Scler Relat Disord. 2018 Aug;24:151-156. doi: 10.1016/j.msard.2018.07.004. Epub 2018 Jul 4.
Multiple sclerosis (MS) and neuromyelitis optica spectrum (NMOSD) cause several symptoms that negatively impact on patient's quality of life. No study has ever conducted to examine the quality of life of MS and NMOSD patients, especially in terms of health utility, among the non-western population. This study aims to examine health utility among MS and NMOSD patients in Thailand.
A multicenter cross-sectional study including 104 MS and 186 NMOSD patients was conducted. Health utility was measured using EQ-5D questionnaire. Demographic data, clinical data and Expanded Disability Status Scales (EDSS) were also collected.
Health utility scores of MS or NMOSD were 0.41 ± 0.36 and 0.41 ± 0.32, respectively. No significant difference between MS and NMOSD in term of health utility score was found. Pain, mobility, and anxiety/depression are the three most affected domains among both MS and NMOSD patients. Age at onset less than 40 years and EDSS score less than or equal to 2.5 were significantly associated with higher health utility score in MS and NMOSD patients.
Our findings clearly demonstrated the negative impact of MS and NMOSD on patients' health-related quality of life. Effective interventions that target pain, mobility, and anxiety/depression should be provided to improve quality of life of these patients. Health utility estimates from this study can be used as an important input for economic evaluations of treatments for MS and NMOSD to inform resource-allocation decisions.
多发性硬化症（MS）和视神经脊髓炎谱系疾病（NMOSD）会引起多种症状，对患者的生活质量产生负面影响。此前尚未有研究针对 MS 和 NMOSD 患者的生活质量进行评估，尤其是在非西方人群中，尚未评估健康效用。本研究旨在评估泰国 MS 和 NMOSD 患者的健康效用。
进行了一项多中心横断面研究，共纳入 104 例 MS 患者和 186 例 NMOSD 患者。使用 EQ-5D 问卷来测量健康效用。收集了人口统计学数据、临床数据和扩展残疾状态量表（EDSS）。
MS 或 NMOSD 的健康效用评分分别为 0.41±0.36 和 0.41±0.32。MS 和 NMOSD 患者的健康效用评分无显著差异。疼痛、移动能力和焦虑/抑郁是 MS 和 NMOSD 患者受影响最严重的三个领域。发病年龄小于 40 岁和 EDSS 评分小于或等于 2.5 与 MS 和 NMOSD 患者的健康效用评分较高显著相关。
我们的研究结果清楚地表明，MS 和 NMOSD 对患者的健康相关生活质量有负面影响。应该为这些患者提供针对疼痛、移动能力和焦虑/抑郁的有效干预措施，以改善其生活质量。本研究的健康效用估计值可作为 MS 和 NMOSD 治疗的经济评估的重要投入，为资源分配决策提供信息。
